Upstream Bio enters into $150M at-the-market offering agreement with Leerink Partners

Upstream Bio, Inc.

Company may sell up to $150M of common stock through Leerink Partners as sales agent.
Agent will receive up to 3.0% commission on gross proceeds from sales.
Offering made under existing shelf registration statement; no obligation to sell any shares.
Sales may be made on Nasdaq or other markets as at-the-market offerings.
Company can suspend or terminate offering at any time.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Upstream Bio, Inc. entered into Sales Agreement with Leerink Partners LLC valued at up to $150,000,000 (effective 2026-03-26).

Action: entry
Agreement: atm program
Counterparty: Leerink Partners LLC
Value: up to $150,000,000
Effective: 2026-03-26

Exact text from the filing

On March 26, 2026, Upstream Bio, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC, as sales agent (the “Agent”), pursuant to which the Company from time to time may offer and sell shares (the “ATM Shares”) of its common stock

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

Upstream Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-126572

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.